Clinical Trial Update: Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of Vadastuximab talirine in combination with azacitidine for previously untreated higher-risk myelodysplastic syndrome was terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Vadastuximab talirine (SGN-CD33A) (vadastuximab talirine)

Snippet

Sponsor: Seagen Inc. | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-12-21